Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGN-1
- Development stage
- Discontinued
- Lead developer
- Capsigen
- Modality
- Gene Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
CGN-1 is an engineered, neurotropic adeno-associated virus (AAV) capsid developed by Capsigen using its proprietary TRADE (Targeted Remote AAV Determinant Engineering) platform. It serves as a proof-of-concept case study demonstrating the platform's ability to create vectors with enhanced tropism for the central nervous system (CNS). While CGN-1 itself is not a clinical drug candidate, the technology behind it is utilized in strategic collaborations, such as with Biogen, to develop gene therapies for CNS and neuromuscular indications. The capsid is designed to enable more efficient and targeted delivery of genetic payloads to brain and spinal cord tissues compared to naturally occurring AAV serotypes.
Beyond the preview
Go deeper on CGN-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGN-1.